New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
10:00 EDTITCI, INCY, COV, WCIC, TRVN, RTEC, GOLD, NUTR, LJPC, KLIC, IVAC, HELI, EPE, APLOn The Fly: Analyst Initiation Summary
Atlas Pipeline Partners (APL) initiated with a Hold at Deutsche Bank... CHC Group (HELI) initiated with a Buy at UBS... EP Energy (EPE) initiated with an Overweight at JPMorgan... Intevac (IVAC) initiated with a Neutral at B. Riley... Kulicke & Soffa (KLIC) initiated with a Buy at B. Riley... La Jolla Pharmaceutical (LJPC) initiated with an Outperform at Wedbush... Nutraceutical (NUTR) initiated with an Outperform at Imperial Capital... Randgold Resources (GOLD) initiated with a Buy at UBS... Rudolph Technologies (RTEC) initiated with a Buy at B. Riley... Trevena (TRVN) initiated with an Outperform at JMP Securities... WCI Communities (WCIC) reinstated with an Outperform at Credit Suisse... Covidien (COV) initiated with a Buy at CRT Capital... Incyte (INCY) coverage assumed with a Buy at BofA/Merrill... Intra-Cellular (ITCI) initiated with an Outperform at Cowen.
News For APL;EPE;HELI;IVAC;KLIC;LJPC;NUTR;GOLD;RTEC;TRVN;WCIC;COV;INCY;ITCI From The Last 14 Days
Check below for free stories on APL;EPE;HELI;IVAC;KLIC;LJPC;NUTR;GOLD;RTEC;TRVN;WCIC;COV;INCY;ITCI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 26, 2014
19:33 EDTCOVCovidien shareholder sues to block sale to Medtronic, Bloomberg reports
Subscribe for More Information
06:46 EDTAPLAtlas Pipeline Partners initiated with an Overweight at JPMorgan
Subscribe for More Information
August 25, 2014
16:37 EDTIVACBecker Drapkin raises stake in Intevac to 8.9% from 7.9%
Subscribe for More Information
08:01 EDTLJPCLa Jolla reports first patient enrolled in LJPC-501 trial
Subscribe for More Information
August 22, 2014
07:01 EDTCOVCovidien acquires Reverse Medical, terms not disclosed
Subscribe for More Information
05:12 EDTHELICHC Group announces investment by Clayton, Dubilier & Rice
CHC Group and Clayton, Dubilier & Rice, or CD&R, announced they have entered into definitive agreements for CD&R managed funds to invest $500M in CHC through the purchase of convertible preferred shares to be issued in a private placement. As part of the transaction, CHC also intends to pursue a $100M rights offering of the convertible preferred shares to existing shareholders. CD&R has agreed to purchase convertible preferred shares, if any are not purchased in the rights offering, which could bring CD&R’s total investment amount up to an aggregate of $600M. CHC plans to use proceeds from the investment primarily to reduce debt and other fixed charges. A portion of the proceeds is expected to be used to redeem $105M of senior unsecured notes and $130M of senior secured notes, plus associated premiums. CHC said remaining proceeds will be used to optimize the mix of owned versus leased aircraft, to further reduce debt opportunistically and for other general corporate purposes. Once the full investment of $600M is deployed, CHC projects it will generate approximately $50M-$60M in annualized incremental free cash flow, on a pro-forma basis beyond previous estimates. CD&R will have a 45% ownership position in CHC Group on an as-converted, pro-forma basis, based on a $500M investment and prior to the rights offering. This percentage could decrease or increase depending on participation of existing shareholders in the rights offering. First Reserve Corporation and its affiliates, which purchased CHC in 2008, would retain approximately 29% ownership in CHC, on a pro-forma basis.
August 20, 2014
16:02 EDTHELICHC Group unit selected to provide engine, component support to AAR Airlift
Subscribe for More Information
07:48 EDTIVACIntevac management to meet with B. Riley
Subscribe for More Information
07:18 EDTCOVMedtronic shares have upside with or without deal, says Deutsche Bank
Deutsche Bank sees limited downside risk and significant upside potential for shares of Medtronic (MDT), with or without the pending Covidien (COV) acquisition. Deutsche says the Q1 results show improving trends and it keeps a Buy rating on Medtronic with an $85 price target.
August 19, 2014
08:22 EDTCOVMedtronic: We will continue to pay significant US taxes following Covidien deal
Subscribe for More Information
August 18, 2014
16:10 EDTCOVCovidien says study shows directional atherectomy safe, effective
Covidien announced that directional atherectomy is "safe and effective as a frontline therapy for the treatment of peripheral arterial disease," according to a Covidien study published online today in the Journal of American College of Cardiology, Cardiovascular Interventions. Results from the DEFINITIVE LE study using Covidien’s TurboHawk and/or SilverHawk directional atherectomy systems demonstrated 95% limb salvage in patients with critical limb ischemia and 78% overall patency in claudicant patients at 12 months.
August 15, 2014
11:42 EDTKLICApplied Materials rises following strong profit, gross margin, order growth
Shares of semiconductor equipment maker Applied Materials (AMAT) are advancing after posting strong third quarter profit, adjusted gross margin, and order growth. WHAT'S NEW: Last night, Applied Materials reported Q3 adjusted earnings per share of 28c and revenue of $2.27B, compared to analysts’ consensus estimates of 27c and $2.29B, respectively. Q3 adjusted gross margin came in at 45.5%, up 260 basis points year-over-year, and up 130 basis points sequentially. Q3 orders of $2.48B, increased 24% year-over-year led by SSG year-over-year order growth of $362M. President and CEO Gary Dickerson said, “We have focused our strategy and investments in areas that have the largest impact for customers while driving improvements in execution and speed across the company. With these actions, we have improved our operating margins for seven quarters in a row and are making substantial progress towards our long-term financial model." WHAT’S NOTABLE: For the fourth quarter, Applied Materials expects adjusted EPS of 25c-29c, versus consensus of 26c. Q4 revenue is expected to be approximately flat, plus or minus 3% sequentially, and up by approximately 10%-17% from the year-ago period, compared to consensus of $2.28B. PRICE ACTION: In late morning trading, Applied Materials rose $1.04, or about 5%, to $22.19 on heavy trading volume. Including today’s advance, the stock has gained approximately 45% over the past twelve months. OTHERS TO WATCH: Other companies in the semiconductor equipment space include Lam Research (LRCX), Kulicke and Soffa (KLIC), and KLA-Tencor (KLAC).
09:33 EDTWCICWCI Communities upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
August 14, 2014
17:16 EDTCOVPaulson & Co gives quarterly update on stakes
Subscribe for More Information
16:32 EDTLJPCLa Jolla reports Q2 EPS (63c), consensus (69c)
Subscribe for More Information
08:13 EDTLJPCLa Jolla receives notice of allowance for additional patent claims
Subscribe for More Information
07:27 EDTCOVJPMorgan a buyer of Medtronic at current levels
Subscribe for More Information
06:15 EDTCOVCovidien risk/reward very favorable, says Citigroup
Subscribe for More Information
August 13, 2014
08:58 EDTITCIIntra-Cellular management to meet with Leerink
Subscribe for More Information
08:35 EDTITCIIntra-Cellular assumed with an Outperform at Leerink
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use